Regulation of megakaryocytopoiesis.
After 35 years of research, a physiological regulator of platelet production has been identified and the recombinant protein is available. With the discovery of thrombopoietin (TPO), its potential use in a wide variety of clinical megakaryocytic and platelet disorders has been expected and clinical trials have been undertaken. To date, the reported encouraging pre-clinical studies indicate that, as with erythropoietin or G-CSF, minimal toxicity can be expected. A potential limiting side-effect of TPO could be the induction of thrombosis. Nevertheless, it is too early to know whether this cytokine will be of major therapeutic importance for patients with life-threatening thrombocytopenia, such as patients undergoing bone marrow transplantation or subjected to a high dose of chemotherapy. Several experimental and clinical studies are still needed to determine the efficacy of TPO in the prevention or the amelioration of bleeding, which is the ultimate goal for the appropriate use of cytokines with haemostatic benefit. Basic and clinical studies on regulators of megakaryocytopoiesis have rapidly progressed. Now, there is no doubt that some of these regulators are effective in correcting haematopoietic disorders of various aetiologies. Studies on negative regulators not only are important to understand the regulation of megakaryocytopoiesis in normal and pathological states but also have a potential clinical application. Some of these regulators have been shown to be effective in the treatment of essential thrombocythaemia and other myeloproliferative disorders. Platelet factor 4 (PF4) and some other chemokines are also capable of protecting progenitor cells from the cytotoxicity of chemotherapeutic drugs. However, detailed investigations are still required to determine the precise mechanism(s) of action of these regulators and to establish the optimal clinical protocols of negative regulators alone or in association with positive regulators for the treatment of various haematological diseases and cancer.
Caen
J P
JP
Institut des Vaisseaux et du Sang, Hôpital Lariboisière, Paris, France.
Han
Z C
ZC
Bellucci
S
S
Alemany
M
M
D000818:Animals; D018925:Chemokines / Q000502:physiology; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000502:physiology; D006410:Hematopoiesis / Q000187:drug effects / Q000502:physiology*; D016298:Hematopoietic Cell Growth Factors / Q000494:pharmacology; D006801:Humans; D016898:Interferon-alpha / Q000494:pharmacology; D008253:Macaca mulatta; D008533:Megakaryocytes / Q000166:cytology* / Q000187:drug effects; D009363:Neoplasm Proteins; D009369:Neoplasms / Q000097:blood; D010978:Platelet Factor 4 / Q000502:physiology; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000502:physiology; D011799:Quinazolines / Q000494:pharmacology / Q000627:therapeutic use; D011833:Radiation Injuries, Experimental / Q000188:drug therapy; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins / Q000494:pharmacology; D013917:Thrombin / Q000502:physiology; D013921:Thrombocytopenia / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D013926:Thrombopoietin / Q000494:pharmacology / Q000502:physiology* / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000502:physiology
D018925:Chemokines; D016207:Cytokines; D016298:Hematopoietic Cell Growth Factors; D016898:Interferon-alpha; D009363:Neoplasm Proteins; D011518:Proto-Oncogene Proteins; D011799:Quinazolines; D018121:Receptors, Cytokine; D053628:Receptors, Thrombopoietin; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C082218:MPL protein, human; D010978:Platelet Factor 4; D013926:Thrombopoietin; D013917:Thrombin; C021139:anagrelide